




Transforming Cardiovascular Treatment with Pulmonary Delivery

InCarda Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers “first pass” to cardiac tissue, presenting a bolus of a drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and more importantly can be patient administered.

Atrial fibrillation (AF) is the most commonly encountered sustained cardiac arrhythmia in clinical practice. The risk of developing AF increases with age and tends to be higher in males than in females. The disease presents a wide spectrum of symptoms and severity and it is progressive. Its current global prevalence is around 34 million patients, which is expected to increase as the general population ages. Paroxysmal AF (PAF) accounts for an estimated 39% of all diagnosed prevalent cases of AF.



A Unique Opportunity

Inhaled delivery of antiarrhythmic drugs presents a unique opportunity to deliver the drug straight to the heart via the lungs as a fast acting patient-administered medicine.

New Paradigm

Leveraging the advent of wearables, mobile monitoring apps, and Bluetooth connected delivery devices, InCarda is providing a revolutionary, highly personalized digital diagnosis and treatment paradigm for atrial fibrillation and other acute cardiac conditions.

InRhythm™ - A breath of fresh air for Paroxysmal Atrial Fibrillation patients.

InRhythm™, our lead product under development, is a patient-administered inhaled antiarrhythmic therapy to treat symptomatic paroxysmal atrial fibrillation (PAF) using approved drugs via inhalation. InRhythm™ is designed to improve the pharmacokinetic profile of the drug to enhance efficacy and improve the safety profile. Initial animal studies have shown rapid conversion of PAF to normal sinus rhythm. InRhythm™ is currently in a Phase 1 trial in healthy volunteers. New therapeutic goals include:

- Patient-administered at home, work or on the go
- Potential to reduce heart-damaging effects of a delayed treatment
- Potential to improve quality of life
- Faster treatment at onset of symptoms
- May reduce the need to visit the ER, ultimately lowering healthcare costs
- Efficacy of an IV with the convenience of a pill

Management Team and Board of Directors



Grace E. Colón, Ph.D.
CEO & President

Experienced Biotech Executive & Entrepreneur

New Science Ventures, Gilead, Affymetrix, Intrexon, McKinsey, MIT



Luiz Belardinelli, M.D.
Chief Medical Officer

Recognized world expert on Cardiac Arrhythmias

Significant regulatory experience; FDA, EMA

Led the development of Adenosine, Ranexa, Lexiscan CV Therapeutics, Gilead



Carlos Schuler, Ph.D.
Chief Operating & Technology Officer

Experienced engineer/scientist

Drug delivery expert; IP expert
Nektar, Anesiva, Incline, ForSight VISION5



Samantha Miller, MSc, MBA
SVP Corporate Development

Corporate & Business Development Expert

Dance Biopharm, Anesiva, Theravance, Nektar, Onyx, P&G

Scientific and Medical Advisors

Narsi Rangachari, M. Pharm.

John Camm, M.D.

C. Michael Gibson, M.S., M.D.

Robert Hamlin DVM, Ph.D.

Peter R. Kowey, M.D.

Chet Leach, Ph.D., DABT

Raymond John Lipicky, M.D.

Gregory M. Marcus, M.D.

Michael A. Matthay, M.D.

John S. Patton, Ph.D.

Jeremy Neil Ruskin, M.D.

David R. Savello, Ph.D.



Robert L. Roden, MS, MBA
VP, Program & Portfolio Management

25+ Years of experience in the biopharmaceutical industry with emphasis on pre-clinical research, portfolio and project management, licensing and alliance management

Gilead, Myogen, Inc.



Reenie McCarthy, J.D.
Director, Morningside Ventures

20+ Years of investment experience

CEO/Board member Stealth Therapeutics

Board seats: DNatrix, CellCentric, Cognoa, InCarda, Excera, Ground Signal, Clean Membranes and Freight Farms



Norbert W. Bischofberger, Ph.D.
CSO & EVP Research and Development, Gilead Sciences

30+ years of recognized R&D expertise bringing several products to market

Gilead, Genentech



Lou Lange, M.D.
(BOD Observer)

Founder/CEO/CSO of CV Therapeutics

20+ yrs of academic and industry experience

Harvard, Washington University

Boards: University of Rochester, BIO, numerous profit and non-profit

Contact InCarda today to learn more about our transformative approach to cardiovascular disease.

INCARDA
Therapeutics, Inc.

California Office

InCarda Therapeutics, Inc.
39899 Balentine Drive, Suite 185
Newark, CA

info@incardatherapeutics.com

Australia Office

InCarda Therapeutics Australia Pty Ltd.
Level 13, 41 Exhibition Street
Melbourne, VIC 3000

www.incardatherapeutics.com